Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease

Journal of Immunology

Volumn 182, Issue 6, 2009, Pages 3892-3901

  McAulay, Karen A ^a   Haque, Tanzina ^b   Urquhart, Gillian ^a   Bellamy, Christopher ^c   Guiretti, Deisy ^a   Crawford, Dorothy H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AG 3 PROTEIN; ANTINEOPLASTIC AGENT; CTL PROTEIN; EPITOPE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 ANTIBODY; NUCLEAR PROTEIN; RITUXIMAB; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; VALACICLOVIR; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BURKITT LYMPHOMA; CELL POPULATION; CELL THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL VARIATION; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INFANT; INFLAMMATION; MALE; MULTICENTER STUDY; MULTIGENE FAMILY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE; TUMOR CELL; TUMOR REGRESSION; VIRUS GENE; AMINO ACID SEQUENCE; CELL CLONE; CELL CULTURE; CELL LINE; COHORT ANALYSIS; GENETICS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; MOLECULAR GENETICS; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; TRANSPLANTATION; VIROLOGY;

AMINO ACID SEQUENCE; CELL LINE, TRANSFORMED; CELLS, CULTURED; CLINICAL TRIALS, PHASE II AS TOPIC; CLONE CELLS; COHORT STUDIES; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HLA ANTIGENS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MOLECULAR SEQUENCE DATA; MULTICENTER STUDIES AS TOPIC; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 65449139488     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803572     Document Type: Article

References (36)

1. Nalesnik, M. A. 2002. Clinicopathologic characteristics of post transplant lymphoproliferative disorders. Rec. Res. Can. Res. 159: 9-18.
2. Paya, C., J. Fung, M. Nalesnik, E. Kieff, M. Green, G. Gores, T. Habermann, R. Wiesner, L. Swinnen, E. Woodle, and J. Bromberg. 1999. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 68: 1517-1525.
3. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187: 1395-1402.
4. Steven, N. M., A. M. Leese, N. E. Annels, S. P. Lee, and A. B. Rickinson. 1996. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 184: 1801-1813.
5. Nalesnik, M. A. 1998. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin. Immunopathol. 20: 325-342.
6. Starzl, T., M. Nalesnik, K. Porter, M. Ho, S. Iwatsuki, B. Griffith, J. Rosenthal, T. Hakada, B. Shaw, and R. Hardestry. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin steroid therapy. Lancet 1: 583-587.
7. Swinnen, L. J., G. M. Mullen, T. J. Carr, M. R. Costanzo, and R. I. Fisher. 1995. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86: 3333-3340.
8. Choquet, S., V. Leblond, R. Herbrecht, G. Socie, A. M. Stoppa, P. Vandenberghe, A. Fischer, F. Morschhauser, G. Salles, W. Feremans, et al. 2006. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 107: 3053-3057.
9. Opelz, G., and B. Dohler. 2004. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4: 222-230.
10. Choquet, S., S. Oertel, V. Leblond, H. Riess, N. Varoqueaux, B. Dörken, and R. Trappe. 2007. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann. Hemat. 86: 599-607.
11. Riddell, S., K. Wantanabe, J. Goodrich, C. Li, M. Agha, and P. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
12. Rooney, C., C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. Krance, M. Brenner, and H. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
13. Rooney, C. M., C. A. Smith, C. Y. Ng, L. C. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogenic transplant recipients. Blood 92: 1549-1555.
14. Comoli, P., R. Maccario, F. Locatelli, U. Valente, S. Basso, A. Garaventa, P. Toma, G. Botti, G. Melioli, F. Baldanti, et al. 2005. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am. J. Transplant. 5: 1415-1422.
15. Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S. R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M. C. Falk, J. Douglass, et al. 1999. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96: 10391-10396.
16. Wilkie, G. M., C. Taylor, M. M. Jones, D. M. Burns, M. Turner, D. Kilpatrick, P. L. Amlot, D. H. Crawford, and T. Haque. 2004. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J. Immunother. 27: 309-316.
17. Haque, T., G. M. Wilkie, C. Taylor, P. L. Amlot, P. Munrad, A. Iley, D. Dombagoda, K. M. Britton, A. J. Swerdlow, and D. H. Crawford. 2002. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360: 436-442.
18. Haque, T., G. M. Wilkie, M. M. Jones, C. D. Higgins, G. Urquhart, P. Wingate, D. Burns, K. McAulay, M. Turner, C. Bellamy, et al. 2007. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
19. + T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 99: 213-223.
20. + naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 104: 2403-2409.
21. Rowe, D., M. Rowe, G. Evan, L. Wallace, P. Farrell, and A. Rickinson. 1986. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J. 5: 2599-2607.
22. Grasser, F. A., P. G. Murray, E. Kremmer, K. Klein, K. Remberger, W. Feiden, G. Reynolds, G. Niedobitek, L. S. Young, and N. Mueller-Lantzsch. 1994. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84: 3792-3798.
23. Deacon, E., G. Pallesen, G. Niedobitek, J. Crocker, L. Brooks, A. Rickenson, and L. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177: 339-349.
24. Savoldo, B., J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y. F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, et al. 2006. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108: 2942-2949.
25. + Hodgkin's disease. J. Exp. Med. 200: 1623-1633.
26. Straathof, K. C. M., C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al. 2005. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904.
27. Einsele, H., E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, U. Grigoleit, A. Moris, H. G. Rammensee, L. Kanz, et al. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922.
28. Rosenberg, S. A., and M. E. Dudley. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101: 14639-14645.
29. Whitney, B. M., A. T. C. Chan, A. B. Rickinson, S. P. Lee, C. K. Lin, and P. J. Johnson. 2002. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J. Med. Virol. 67: 359-363.
30. Kelly, G. L., A. E. Milner, R. J. Tierney, D. S. G. Croom-Carter, M. Altmann, W. Hammerschmidt, A. I. Bell, and A. B. Rickinson. 2005. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79: 10709-10717.
31. + T-helper 1 responses. J. Virol. 75: 8649-8659.
32. + T helper cells. Eur. J. Immunol. 34: 2500-2509.
33. Bleakley, M., and Riddel, S. R. 2004. Molecules and mechanisms of graft-versus-leukaemia effect. Nat. Rev. 4: 371-380.
34. + T-cell reactivity. J. Virol. 79: 5477-5488.
35. Leen, A. M., G. D. Myers, U. Sili, M. H. Huls, H. Weiss, K. S. Leung, G. Carrum, R. A. Krance, C. C. Chang, J. J. Molldrem, et al. 2006. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12: 1160-1166.
36. Leen, A. M., and H. E. Heslop. 2008. Cytotoxic T lymphocytes as immunetherapy in haematological practice. Br. J. Haematol. 143: 169-179.